A typical CJC-1295 DAC cycle length runs 8 to 12 weeks, with weekly dosing and bloodwork monitoring. Learn how researchers structure on and off periods.
Most CJC-1295 DAC cycles last 8 to 12 weeks, dosed once weekly at 1 to 2 mg, followed by a break of at least 4 weeks. A 12-week run is the most commonly discussed CJC-1295 DAC cycle length, though some researchers extend to 16 weeks with closer bloodwork. CJC-1295 DAC is not FDA-approved for human use in the United States.
Cycle length matters because the DAC, or Drug Affinity Complex, pushes the peptide's half-life out to roughly 6 to 8 days. The compound stays active long after each injection, so 12 weeks of CJC-1295 DAC is a far larger cumulative exposure than 12 weeks of a short-acting GHRH peptide.
What CJC-1295 DAC Is and Why Length Matters
CJC-1295 DAC is a modified growth hormone-releasing hormone (GHRH) analog. The DAC portion binds to albumin in the bloodstream, which slows clearance and keeps the peptide active for days rather than minutes.
That long half-life is the whole reason cycle length is such a common question. Short-acting GHRH peptides such as mod GRF 1-29 are usually injected two or three times daily, while CJC-1295 DAC is typically injected once a week.
Because the peptide increases growth hormone release and, indirectly, IGF-1, longer cycles mean sustained elevation of those markers. That is the main argument for keeping a CJC-1295 DAC cycle to 8 to 12 weeks instead of running it indefinitely.
Common CJC-1295 DAC Cycle Lengths Compared
Different communities describe very different protocols. The table below summarizes the ranges most often discussed for a cjc-1295 dac cycle length.
| Protocol | Cycle length | Typical weekly dose | Why people choose it |
|---|---|---|---|
| Conservative | 8 weeks | 1 mg | Shortest exposure and easiest monitoring |
| Standard | 12 weeks | 1 to 2 mg | Most widely discussed length and reaches steady state |
| Extended | 16 weeks | 2 mg | For users tracking bloodwork closely throughout |
| Continuous | 6 months or longer | 1 to 2 mg | Not recommended without medical supervision |
There is no confirmed optimal cycle length for CJC-1295 DAC. Anyone considering this peptide should discuss it with a healthcare professional, because CJC-1295 DAC has not been approved by the FDA for human use.
How Dosing Frequency Shapes the Cycle
Most protocols use 1 mg or 2 mg per week. Because of the long half-life, CJC-1295 DAC reaches steady blood levels after roughly four to five half-lives, which works out to about 4 to 6 weeks.
That has a practical consequence: cycles shorter than about 6 weeks never reach full steady state. An 8-week or 12-week window gives the compound time to build up while keeping total exposure finite.
Weekly dosing is the norm. Some users split the weekly amount into two injections, but the difference in blood levels is small given how slowly the peptide clears.
A cjc 1295 dac only cycle versus a stack
A cjc 1295 dac only cycle means no added GHRP or second GHRH. It is the simplest way to track effects, because any change in IGF-1 or side effects can be attributed to a single compound.
Stacking is still common. Many people combine CJC-1295 DAC with a GHRP such as ipamorelin, and it helps to know what is ipamorelin peptide before adding a second injection to the routine.
| Approach | Compounds | Typical cycle | Trade-off |
|---|---|---|---|
| CJC-1295 DAC only | CJC-1295 DAC | 8 to 12 weeks | Simpler to evaluate, smaller GH pulse |
| Stacked with a GHRP | CJC-1295 DAC plus ipamorelin or similar | 8 to 12 weeks | Potentially larger effect, harder to attribute side effects |
Time Off Between CJC-1295 DAC Cycles
A widely repeated rule of thumb is time on equals time off. Twelve weeks on is followed by roughly 12 weeks off, while an 8-week cycle gets at least 4 to 8 weeks off.
The purpose of the break is to let IGF-1 and natural growth hormone pulsatility drift back toward baseline, and to reassess whether the protocol is worth continuing at all.
Monitoring and Safety During a Cycle
Bloodwork is the most useful tool for deciding whether a cycle should continue or end. Markers commonly discussed include IGF-1, fasting glucose, and HbA1c.
Sustained IGF-1 elevation is a theoretical concern, and CJC-1295 DAC can affect blood sugar in some users. Persistent numbness, tingling, swelling, or joint pain are signals that the dose or cycle length may need to be reduced.
Reconstitution supplies are part of the picture too. Research peptides are typically mixed with bacteriostatic water, and searches for bacteriostatic water walgreens come up often because it is not standard pharmacy stock in most states.
Prescription growth hormone is a different product with a very different oversight picture. Somatropin cost is also dramatically higher than research peptide pricing, which is one reason people explore alternatives in the first place.
None of this makes CJC-1295 DAC safe or legal for human use. It is not FDA-approved, and long-term human safety data simply do not exist.
How CJC-1295 DAC Compares With Other Research Compounds
People researching this peptide usually look at a few unrelated compounds at the same time. Another frequently compared pair in peptide discussions is aod 9604 vs mots-c, although neither works through growth hormone release the way CJC-1295 DAC does.
What separates CJC-1295 DAC from most of those options is its duration. A single weekly injection keeps the peptide active all week, which is why cycle length and break periods get more attention here than with daily-dosed compounds.
Bottom Line on CJC-1295 DAC Cycle Length
An 8-week to 12-week cycle at 1 to 2 mg per week is the range most often described, followed by a break of 4 weeks or longer. Sixteen weeks is the outer edge of what people typically attempt, and continuous use is not advisable without medical oversight.
Cycle length is a starting point, not a prescription. Dose, bloodwork, and individual response all matter more than a number copied from a forum.
Frequently Asked Questions
How long should a CJC-1295 DAC cycle be?
Most protocols run 8 to 12 weeks at 1 to 2 mg injected once weekly. An 8-week cycle is the shortest option that still reaches steady blood levels, and 12 weeks is the most commonly discussed length. Anyone extending beyond 16 weeks should be doing so only with medical supervision and regular bloodwork.
Do you need to cycle off CJC-1295 DAC?
Yes, breaks are standard practice in almost every protocol discussed. The common rule is time on equals time off, so a 12-week cycle is followed by about 12 weeks off. The break allows IGF-1 and natural growth hormone patterns to return toward baseline before another run begins.
Can you stack CJC-1295 DAC with ipamorelin?
Stacking CJC-1295 DAC with a GHRP like ipamorelin is frequently described in research discussions, usually over the same 8 to 12 week window. Keep in mind that combining compounds makes it harder to tell which one caused a given effect or side effect. CJC-1295 DAC and ipamorelin are both unapproved for human use in the United States.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.